title: [Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure].
abstract: Recently, the safety and effectiveness of bortezomib for patients with multiple myeloma and renal failure has been reported. In this study, we retrospectively analyzed the 8 myeloma patients with renal failure who have received bortezomib in our hospital.One patient had already required constant hemodialysis before bortezomib.Bortezomib treatment was performed for 229 days, during which time it was injected 30 times.The other 2 patients with chronic renal failure also showed no further renal impairment due to bortezomib.In the remaining 5 patients, serum creatinine levels decreased through 2 cycles(total: 8 injection)of bortezomib treatment.Two patients were complicated with herpes zoster, and 2 patients were complicated with neuropathy in grade 3.We showed the safety and efficacy of bortezomib in Japanese patients with multiple myeloma complicated with renal failure.We should positively consider the therapeutic choice of bortezomib for the refractory myeloma with renal failure.
authors.affiliation: Dept. of Internal Medicine, Matsuyama Red-Cross Hospital.
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Muta
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Nakanishi
authors.forename: Megumi
authors.initials: M
authors.lastname: Yasunaga
authors.forename: Shozo
authors.initials: S
authors.lastname: Senba
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Murakami
authors.forename: Shin
authors.initials: S
authors.lastname: Kan
authors.forename: Yoko
authors.initials: Y
authors.lastname: Ueda
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Fujisaki
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001897:Boronic Acids / Q000009:adverse effects* / Q000627:therapeutic use; D000069286:Bortezomib; D003401:Creatine / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy*; D011719:Pyrazines / Q000009:adverse effects* / Q000627:therapeutic use; D051437:Renal Insufficiency / Q000097:blood / Q000150:complications / Q000503:physiopathology*
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D003401:Creatine